Skip to main content
. Author manuscript; available in PMC: 2014 Sep 19.
Published in final edited form as: JAMA. 2011 Oct 12;306(14):1549–1556. doi: 10.1001/jama.2011.1437

Table 5. Secondary Endpoints.

Placebo
(n=8,696)
Vitamin E alone
(n=8,737)
Selenium alone
(n=8,752)
Vitamin E + selenium
(n=8,702)
Colorectal Cancer 75 85 74 93
 Hazard ratio (99% CI) 1.09 (0.72, 1.64) 0.96 (0.63, 1.46) 1.21 (0.81, 1.81)
 p-value p=0.60 p=0.79 p=0.22
Lung Cancer 92 104 94 104
 Hazard ratio (99% CI) 1.11 (0.76, 1.61) 1.02 (0.70, 1.50) 1.11 (0.76, 1.62)
 p-value p=0.49 p=0.89 p=0.48
All other primary cancers (excludes prostate, includes colorectal and lung) 579 570 557 594
 Hazard ratio (99% CI) 0.97 (0.83, 1.14) 0.96 (0.83, 1.13) 1.02 (0.88, 1.19)
 p-value p=0.65 p=0.54 p=0.74
All cancers (including prostate) 1108 1190 1132 1149
 Hazard ratio (99% CI) 1.07 (0.96, 1.19) 1.02 (0.92, 1.14) 1.02 (0.92, 1.14)
 p-value p=0.13 p=0.59 p=0.60
 Deaths (all cause) 564 571 551 542
 Hazard ratio (99% CI) 1.01 (0.86, 1.17) 0.98 (0.84, 1.14) 0.96 (0.82, 1.12)
 p-value p=.91 p=.67 p=.47
October 23, 2008
Diabetes* 669 700 724 660
 Relative Risk (99% CI) 1.04 (0.90 – 1.18) 1.07 (0.94 – 1.22) 0.97 (0.86 – 1.11)
 p-value p = 0.47 p = 0.16 p = 0.61
July 5, 2011
Diabetes* 869 918 913 875
 Relative Risk (99% CI) 1.05 (0.93 – 1.17) 1.04 (0.93 – 1.17) 0.99 (0.89 – 1.12)
 p-value p = 0.29 p = 0.34 p = 0.91
Cardiovascular events, grade 4 or higher** 969 909 939 943
 Hazard Ratio (99% CI) 0.93 (0.83,1.05) 0.97 (0.86,1.09) 0.97 (0.86,1.09)
 p-value p = 0.11 p = 0.45 p = 0.51

Date of data freeze for initial publication

*

Prevalent cases at baseline and men who never submitted a form with a diabetes assessment are excluded from the analysis.

**

Time to first reported cardiovascular event, cardiovascular procedure (e.g., CABG), or hemorrhagic stroke, all men. Cardiovascular endpoints were not centrally adjudicated.